Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | RGS12 | O14924 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin Ag 879 SCHEMBL607702 | 1.00 | MAPT (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| Tyrphostin Ag 879 SCHEMBL607703 | 1.00 | MAPT (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL25736022 | 0.88 | MEN1 (0.78) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL11093690 | 0.86 | EGFR (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL20333049 | 0.86 | MEN1 (0.76) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL11093692 | 0.86 | EGFR (1.00) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL8346188 | 0.81 | EGFR (0.76) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL6286531 | 0.81 | MAPT (0.68) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL6278934 | 0.81 | MAPT (0.68) | MAPTKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3244723 | 0.80 | EGFR (0.74) | MAPTKMT2AALDH1A1MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709874-A1 | MODULATORS OF PROTEIN SECRETION | Sanofi (FR) | 2026-03-18 | — | — | EP | claimed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| WO-2024231896-A1 | MODULATORS OF PROTEIN SECRETION | SANOFI (FR) | 2024-11-14 | — | — | WO | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240287616-A1 | METHODS OF DETECTING NTRK FUSION PROTEINS | STRATA ONCOLOGY INC (US) | 2024-08-29 | — | — | US | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION | 2024-07-04 | — | — | US | claimed |
| EP-3303610-B1 | COMPOSITIONS AND METHODS FOR SCREENING SOLID TUMORS | QUEST DIAGNOSTICS INVEST INC (US) | 2024-05-08 | — | — | EP | claimed |
| EP-4355917-A1 | METHODS OF DETECTING NTRK FUSION PROTEINS | Strata Oncology, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| EP-4110404-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION (US) | 2023-01-04 | — | — | EP | claimed |
| CN-115515643-A | Modified binding polypeptides for optimized drug conjugation | 建新公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2022266551-A1 | METHODS OF DETECTING NTRK FUSION PROTEINS | Strata Oncology, Inc. (US) | 2022-12-22 | — | — | WO | claimed |
| US-11525008-B2 | Methods and pharmaceutical compositions for the treatment of lung cancer | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-12-13 | — | — | US | claimed |
| CN-115474430-A | Composition for treatment and/or prevention of coronavirus infection | 弗劳恩霍夫应用研究促进协会 | 2022-12-13 | — | — | CN | claimed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | claimed |
| EP-3980563-A2 | NTRK FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| US-6596878-B2 | Protein kinase inhibitor compositio; used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR. | YISSUM RESEARCH & DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) | 2003-07-22 | — | — | US | claimed |
| US-5981569-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | MAPT 2245/4885KMT2A 4235/4885ALDH1A1 4003/4885 |
| US-11525008-B2 | Methods and pharmaceutical compositions for the treatment of lung cancer | FHIT, MAT2A, MAT1A | MAPT 4334/4885KMT2A 289/4885ALDH1A1 1045/4885 |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | FCGR3B, CD2BP2, FCGR2A | MAPT 1888/4885KMT2A 3604/4885ALDH1A1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.